Cargando…

Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom

Currently, the 13-valent pneumococcal conjugate vaccine (PCV13) is administered under a 1+1 (1 primary dose) pediatric schedule in the United Kingdom (UK). Higher-valency PCVs, 15-valent PCV (PCV15), or 20-valent PCV (PCV20) might be considered to expand serotype coverage. We evaluated the cost-effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Michele, Lucas, Aaron, Mendes, Diana, Vyse, Andrew, Mikudina, Boglarka, Czudek, Carole, Ellsbury, Gillian Frances, Perdrizet, Johnna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386052/ https://www.ncbi.nlm.nih.gov/pubmed/37514984 http://dx.doi.org/10.3390/vaccines11071168

Ejemplares similares

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
por: Warren, Sophie, et al.
Publicado: (2023)

576. Burden of Pneumococcal Disease Due to Serotypes Covered by the 13-Valent and New Higher-Valent Pneumococcal Conjugate Vaccines in All Children and Children at Risk in the United States
por: Huang, Liping, et al.
Publicado: (2022)

Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium
por: Wilson, Michele R., et al.
Publicado: (2021)

Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective
por: Li, Xiuyan, et al.
Publicado: (2023)

Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia
por: Perdrizet, Johnna, et al.
Publicado: (2021)

Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
por: Ghia, Canna J., et al.
Publicado: (2021)

Correction to: Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
por: Ghia, Canna J., et al.
Publicado: (2021)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands
por: Wilson, Michele, et al.
Publicado: (2023)

Pediatric outpatient visits and antibiotic use attributable to higher valency pneumococcal conjugate vaccine serotypes
por: King, Laura M, et al.
Publicado: (2023)

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
por: Lee, Hyunju, et al.
Publicado: (2014)

1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age
por: Wasserman, Matt D., et al.
Publicado: (2021)

A Response to: Letter to the Editor Regarding ‘Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age’
por: Rozenbaum, Mark H., et al.
Publicado: (2022)

Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
por: Perdrizet, Johnna, et al.
Publicado: (2021)

2728. Proportion of Invasive Pneumococcal Disease Potentially Covered by Current and Next-Generation of Higher-Valency Pneumococcal Conjugate Vaccines in Canada, 2010–2016
por: Dion, Stephane B, et al.
Publicado: (2019)

Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States
por: Perdrizet, Johnna, et al.
Publicado: (2023)

1737. Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine
por: Rozenbaum, Mark, et al.
Publicado: (2023)

A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Perdrizet, Johnna, et al.
Publicado: (2022)

Response to Gomez et al.’s Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Perdrizet, Johnna, et al.
Publicado: (2022)

Identifying UK travellers at increased risk of developing pneumococcal infection: a novel algorithm
por: Ellsbury, Gillian, et al.
Publicado: (2021)

Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media
por: Izurieta, Patricia, et al.
Publicado: (2022)

Implementation challenges and real-world impacts of switching pediatric vaccines: A global systematic literature review
por: Patikorn, Chanthawat, et al.
Publicado: (2023)

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population
por: Lytle, Derek, et al.
Publicado: (2023)

Community-acquired pneumonia in the United Kingdom: a call to action
por: Chalmers, James, et al.
Publicado: (2017)

Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK
por: Wasserman, M., et al.
Publicado: (2018)

Higher valent Pneumococcal Conjugate Vaccines: is it a roller coaster?
por: Oligbu, Godwin
Publicado: (2020)

Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease
por: Huang, Liping, et al.
Publicado: (2023)

Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia
por: Suwantika, Auliya A., et al.
Publicado: (2020)

Assessing the Role of Infant and Toddler MenACWY Immunisation in the UK: Does the Adolescent MenACWY Programme Provide Sufficient Protection?
por: Schley, Katharina, et al.
Publicado: (2023)

Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis
por: Pugh, Sarah, et al.
Publicado: (2020)

Pneumococcal Colonization in Healthy Adult Research Participants in the Conjugate Vaccine Era, United Kingdom, 2010–2017
por: Adler, Hugh, et al.
Publicado: (2019)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
por: Ansaldi, Filippo, et al.
Publicado: (2020)

Changes in the Serotype Distribution among Antibiotic Resistant Carriage Streptococcus pneumoniae Isolates in Children after the Introduction of the Extended-Valency Pneumococcal Conjugate Vaccine
por: Lee, Joon Kee, et al.
Publicado: (2017)

Changes in the Serotype Distribution among Antibiotic Resistant Carriage Streptococcus pneumoniae Isolates in Children after the Introduction of the Extended-Valency Pneumococcal Conjugate Vaccine
por: Lee, Joon Kee, et al.
Publicado: (2017)

Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations
por: Naucler, Pontus, et al.
Publicado: (2017)

Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England
por: Campling, James, et al.
Publicado: (2020)

Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
por: Melegaro, Alessia, et al.
Publicado: (2010)

Optimizing the benefits of pneumococcal vaccination in the Kingdom of Saudi Arabia
por: Azhar, Esam I., et al.
Publicado: (2016)

Cost-effectiveness analysis of a multifactorial fall prevention intervention in older home care clients at risk for falling
por: Isaranuwatchai, Wanrudee, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dobta6vn2215td1kvhbi8h5rf9